Trial Profile

Exploring the Potential of Dual Kinase JAK 1/2 Inhibitor Ruxolitinib (INC424) With Reduced Intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 06 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ruxolitinib (Primary) ; Antithymocyte globulin; Busulfan; Ciclosporin; Fludarabine; Methotrexate; Tacrolimus
Indications Graft-versus-host disease; Myelofibrosis
Focus Therapeutic Use

Most Recent Events

01 Jan 2026 Results published in the Transplantation and Cellular Therapy
28 Feb 2019 Status changed from active, no longer recruiting to discontinued.
09 Feb 2019 This study has been completed in United Kingdom.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com